成人心脏源性休克患者平均动脉压的个体化治疗 (CARDIOPAM)
前瞻性、随机、多中心、对照试验评估成人患者心源性休克期间平均动脉压的个体化治疗
Cardiogenic shock is a life-threatening condition characterized by inadequate cardiac output, leading to organ hypoperfusion and high mortality. Maintaining mean arterial pressure (MAP) is crucial, but standard targets may be insufficient due to venous congestion. Central venous pressure (CVP) can help assess effective perfusion pressure. This study investigates whether a personalized MAP target adjusted by CVP improves organ function and survival compared to standard MAP management.
研究概览
详细说明
Cardiogenic shock is a severe and life-threatening condition. Its prognosis remains very poor with a high mortality rate (up to 50% in clinical series) despite recent therapeutic advances. Current recommendations suggest the use of inotropes and vasopressors to maintain tissue perfusion and prevent organ failure.
During cardiogenic shock, the mean arterial pressure (MAP) level is associated with survival. A post hoc analysis of a recent randomized trial found increased mortality among patients in cardiogenic shock whose average MAP was <70 mmHg during the first 36 hours after randomization, compared to patients with MAP ≥70 mmHg (58% vs. 29%, p<0.01). Another observational study found higher mortality among patients with a mean MAP <65 mmHg during the first 24 hours of shock compared to those with MAP ≥65 mmHg (57% vs. 28%, p<0.001). In this study, the incidence of renal failure was also inversely associated with MAP level. The optimal MAP target remains unknown during cardiogenic shock.
Due to the characteristic venous congestion, the effective perfusion pressure may be very low during cardiogenic shock despite MAP being within the usual target (65 mmHg). Furthermore, increased central venous pressure (CVP) is associated with higher mortality during cardiogenic shock. Considering venous congestion by measuring or estimating CVP is necessary to assess the effective perfusion pressure (MAP minus CVP) in order to protect against organ dysfunction. In this perspective, the MAP target should be increased by the value of the CVP.
The investigators hypothesize that personalizing the MAP target (to achieve an effective perfusion pressure of 65 mmHg) improves organ perfusion and survival during cardiogenic shock compared to the usual MAP target of 65 mmHg.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Armand MEKONTSO DESSAP, MD
- 电话号码:+ 33 1 45 17 85 06
- 邮箱:armand.dessap@aphp.fr
学习地点
-
-
-
Amiens、法国、80000
- 尚未招聘
- CHU d'Amiens-Picardie
-
接触:
- Christophe BEYLS, MD
-
Créteil、法国、94010
- 招聘中
- Hôpital Henri Mondor
-
接触:
- Armand MEKONTSO DESSAP, MD
-
Massy、法国、91300
- 尚未招聘
- Hôpital Privé Jacques Cartier
-
接触:
- Wulfran BOUGOUIN, MD
-
Neuilly-sur-Seine、法国、92200
- 招聘中
- CMC Ambroise Paré - Hartmann
-
接触:
- Guillaume GERI, MD
-
Orléans、法国、45100
- 尚未招聘
- CHU d'Orléans
-
接触:
- Marc GORALSKI, MD
-
Paris、法国、75014
- 尚未招聘
- Hôpital Cochin
-
接触:
- Alain CARIOU, MD
-
Paris、法国、75010
- 尚未招聘
- Hôpital Lariboisière
-
接触:
- Bruno MÉGARBANE, MD
-
Saint-Cyr-sur-Loire、法国、37540
- 尚未招聘
- Clinique NCT + /Saint-Gatien
-
接触:
- Aurélien SEEMANN, MD
-
Saint-Denis、法国、93200
- 尚未招聘
- Centre Cardiologique du Nord
-
接触:
- Tristan MORICHAUBEAUCHANT, MD
-
Strasbourg、法国、67000
- 尚未招聘
- CHRU de Strasbourg
-
接触:
- Hamid MERDJI, MD
-
Toulouse、法国、31000
- 尚未招聘
- CHU de Toulouse
-
接触:
- Clément DELMAS, MD
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Aged ≥18 years
- Cardiogenic shock state, according to the consensus definition,
- SCAI (Society for Cardiovascular Angiography and Interventions) classification ≥ C
- Consent from the patient or close relative / trusted person or emergency inclusion procedure
- Benefiting fromciary of a social security scheme
Exclusion Criteria:
- Catecholamine infusion for more than 24 consecutive hours;
- CVP < 5 mm Hg at inclusion;
- MAP > 70 mmHg at inclusion;
- Chronic kidney disease stage G4 (defined by an eGFR between 15-29 ml/min/1.73 m²) or G5 (defined by an eGFR less than 15 ml/min/1.73 m²) according to the KDIGO CKD classification at inclusion;
- Chronic dialysis or presence of renal replacement therapy criteria at inclusion ;
- Recovered cardiopulmonary arrest within 7 days prior to inclusion;
- Patient already on mechanical circulatory support at inclusion before enrollment (patients who receive support after inclusion will not be excluded);
- Primary diagnosis of tamponade, pulmonary embolism, or septic shock;
- Hypersensitivity to norepinephrine tartrate or to any of the following excipients: sodium chloride, hydrochloric acid or sodium hydroxide water for injectable preparations;
- Absence of central venous access;
- Known pregnancy or current breastfeeding;
- Under legal guardianship, curatorship, or judicial protection.
学习计划
研究是如何设计的?
设计细节
- 主要用途:其他
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:个性化MAP
|
Patients receive blood pressure management targeting a personalized MAP ranging from 65 mmHg + CVP to 75 mmHg + CVP, without exceeding 90 mmHg.CVP is measured via a central venous catheter positioned in the superior vena cava. After 48 hours, if tissue perfusion is restored, the MAP target may be reduced to 65-70 mmHg. |
|
有源比较器:标准平均动脉压
|
Patients receive blood pressure management aiming for a standard MAP target of 65-70 mmHg, according to international guidelines for cardiogenic shock management. |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
主要终点将是死亡率、心脏机械循环支持的使用以及严重肾功能衰竭的复合终点。
大体时间:随机分组后7天和28天
|
随机分组后7天和28天
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
重症监护病房(ICU)及院内死亡率
大体时间:随机分组后第28天和第90天
|
随机分组后第28天和第90天
|
|
|
在重症监护病房和医院的住院时间
大体时间:随机分组后28天和90天
|
随机分组后28天和90天
|
|
|
需要心脏机械循环支持的患者比例
大体时间:随机化后28天
|
随机化后28天
|
|
|
需要肾脏替代治疗的患者比例
大体时间:随机分组后28天
|
随机分组后28天
|
|
|
正性肌力药和血管加压药支持持续时间
大体时间:随机分组后28天
|
随机分组后28天
|
|
|
使用机械通气
大体时间:随机分组后28天
|
随机分组后28天
|
|
|
无呼吸机天数
大体时间:随机分组后28天
|
随机分组后28天
|
|
|
乳酸水平演变
大体时间:随机化后5天
|
随机化后5天
|
|
|
斑点评分评估
大体时间:随机化后5天
|
随机化后5天
|
|
|
毛细血管再充盈时间评估
大体时间:随机分组后5天
|
随机分组后5天
|
|
|
持续室性和/或室上性心律失常患者的比例
大体时间:随机分组后5天
|
随机分组后5天
|
|
|
卒中、非脑缺血、新发或复发性心肌梗死患者的比例
大体时间:随机分组后28天
|
随机分组后28天
|
|
|
D28时的净临床获益(无血栓事件或大出血的生存期)。
大体时间:随机分组后28天
|
随机分组后28天
|
|
|
住院期间随机分组后接受新特定治疗的患者比例
大体时间:随机分组后28天
|
随机分组后28天
|
|
|
Proportion of patients with severe acute kidney injury (stage 2 and stage 3 according to KDIGO AKI classification)
大体时间:7 days after randomization
|
Defined as stage 2 or stage 3 according to the Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury classification |
7 days after randomization
|
|
Evolution of the vasoactive inotropic score (VIS)
大体时间:5 days after randomization
|
The clinical outcome is defined based on the Vasoactive Inotropic Score (VIS), according to published standard references |
5 days after randomization
|
|
Evaluation of Sequential Organ Failure Assessment (SOFA) score
大体时间:5 days after randomization
|
The clinical outcome is defined based on the Sequential Organ Failure Assessment (SOFA) score, according to published standard references |
5 days after randomization
|
|
Proportion of patients with major bleeding, defined according to the ISTH classification
大体时间:28 days after randomization
|
Defined according to the International Society on Thrombosis and Haemostasis (ISTH) classification. |
28 days after randomization
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.